samedi 10 septembre 2011

Press review (September 10, 2011) – Revue de presse (10 septembre 2011)

Annual Breast Exams, Mammograms Still Key to Detecting Breast Cancer
Third of tumors were spotted in a breast exam by a doctor or a self-exam, study finds.
By Amanda Gardner. In U.S. News & World Report

Zytiga® Approved in the European Union for Metastatic Castration-Resistant Prostate Cancer
Janssen-Cilag International NV announced today that, after an accelerated regulatory review process by the European Medicines Agency (EMA) and following a positive CHMP opinion on the 22 July 2011, the European Commission has approved the marketing authorisation for ZYTIGA® (abiraterone acetate), a novel, once-daily, oral, androgen biosynthesis inhibitor. Abiraterone acetate is approved, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
PR Newswire UK (press release)

Worldwide cancer rates 'could be cut by 2.8m with healthier lifestyles and diets'
World Cancer Research Fund study says disease can be widely prevented as UN prepares to hold summit to tackle soaring rates.
By Sarah Boseley. In The Guardian

NICE changes mind to back Takeda bone cancer drug
Britain's health costs watchdog NICE has decided to back Japanese group Takeda's bone cancer drug Mepact after re-assessing the impact of a discount on the medicine for patients in the state-funded National Health Service (NHS).
By Kate Kelland, Dan Lalor. Reuters

Beat enzyme, curb cancer: study
Scientists from the Genome Institute of Singapore (GIS), an institute of the Agency for Science, Technology and Research (A*STAR), and their colleagues at the National University of Singapore (NUS), have uncovered a new way to target EZH2, an enzyme that promotes the estrogen receptor-negative breast cancer, a type of breast cancer that is aggressive and unresponsive to current forms of treatment.
In ScienceAlert

UK NICE Rejects 3 Drugs for Metastatic Colorectal Cancer‎
Three targeted therapies — bevacizumab (Avastin), cetuximab (Erbitux), and panitumumab (Vectibix, Amgen) — have been rejected in the United Kingdom for use in patients with metastatic colorectal cancer that has progressed after first-line therapy.
By Zosia Chustecka. In Medscape

Cancer Research UK opens olaparib and temozolomide Phase I combination trial in glioblastoma
Cancer Research UK's Drug Development Office has opened a trial of a new combination of drugs for the treatment of patients with brain cancer.

TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk‎‎
But review also finds the drugs don't heighten risks for other cancers.
In U.S. News & World Report

Bisphosphonate Cancer Risk Divides FDA Officials‎‎
Food and Drug Administration officials disagree over whether the long-term use of oral bisphosphonates increases the risk of esophageal cancer, background documents released before an advisory committee meeting show.
By Martin Berman-Gorvine. In The Oncology Report

Novel Approach Scores First Success Against Elusive Cancer Gene
Dana-Farber Cancer Institute scientists have successfully disrupted the function of a cancer gene involved in the formation of most human tumors by tampering with the gene's "on" switch and growth signals, rather than targeting the gene itself. The results, achieved in multiple myeloma cells, offer a promising strategy for treating not only myeloma but also many other cancer types driven by the gene MYC, the study authors say. Their findings are being published by the journal Cell on its website Sept. 1 and in its Sept. 16 print edition.
In Newswise

Cancers du sein : découverte d'un marqueur de risque de métastases pulmonaires‎
Des chercheurs français ont identifié un marqueur du risque de développer des métastases pulmonaires chez les femmes atteintes de cancers du sein, selon des travaux publiés mardi. En agissant sur ce marqueur, dénommé "Kindlin-1", les chercheurs espèrent pouvoir bloquer la prolifération des cellules tumorales et ainsi contenir le pouvoir agressif des tumeurs à fort risque de dissémination pulmonaire.

Novartis: feu vert de Bruxelles pour l'Afinitor
Novartis a reçu l'approbation de la Commission européenne pour la commercialisation de son médicament Afinitor dans le traitement de patients atteints de tumeurs neuro-endocrines du pancréas à un stade avancé.
Dans L’Express

Un médicament désormais contre-indiqué chez les enfants cancéreux.
Un médicament utilisé en cancérologie, le Cardioxane des laboratoires Novartis, est désormais contre-indiqué chez les enfants et les adolescents en raison d'un risque accru de cancers secondaires à ce traitement, selon l'Agence française de sécurité sanitaire des produits de santé (Afssaps).

Tchernobyl : quelles conséquences pour la France ?‎
Les données dont on dispose sur les retombées du nuage de Tchernobyl sur la France sont éparses et interprétées de diverses façons. Une chose est sûre, l'augmentation des cancers de la thyroïde avait commencé bien avant 1986.
Par André Aurengo. Dans Pour la Science

Travailler debout, ça vous tente?
Alors que certains salariés prônent la sieste en entreprise, d'autres militent pour travailler debout. D'après une étude de l'American Cancer Society, rester assis plus de six heures par jour accroitrait de 37% le risque de mort prématurée chez les femmes.
Par Elodie Bousquet. Dans L’Express

Aucun commentaire:

Enregistrer un commentaire